Lund, Sweden – 28 September 2015, – BioInvent International (OMXS: BINV) announced today that Michael Oredsson, President and CEO of BioInvent, will make a corporate presentation at the Ladenburg Thalmann 2015 Healthcare Conference on September 29th at 3 p.m. Eastern Time (9 p.m. CET). The conference is being held at the Sofitel Hotel in New York City.  

A live audio webcast of Mr. Oredsson’s presentation will be available in the investor section of BioInvent’s website, www.bioinvent.se, where it will also be archived for 90 days.

To the editors:

About BioInvent
BioInvent International AB develops immune oncology drugs. With one of the world’s largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. This makes it possible to develop proprietary drug projects, but also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

For further information, please contact:
Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30
[email protected]

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
[email protected]  
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same was as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 28 September, 2015.